Biotech AssistantIndependent biopharma research
BIOTECH ASSISTANT / FIELD NOTES

Vir schedules Phase 3 elebsiran–tobevibart results for The Liver Meeting

Company / institutional announcement · Vir Biotechnology / Business Wire

Source published: · Event / reporting date: 2026-11-06

Site published: 2026-11-06 · Updated: 2026-11-06

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What changed

Vir Biotechnology announced that Phase 3 ECLIPSE 1 results for elebsiran plus tobevibart in chronic hepatitis delta will be presented on November 8, with an investor discussion on November 9. Elebsiran is an HBV-targeting siRNA; tobevibart is an antibody. The release announces the forthcoming readout and expanded Phase 2 presentations but does not disclose the Phase 3 numerical results.

Why it may matter

Analysis: The readout may clarify the contribution of siRNA–antibody combinations to hepatitis delta treatment, but conclusions must await the actual clinical results.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Oligonucleotide Therapeutics & Delivery

Related updates

Nitto Denko Avecia

Avecia and EnPlusOne agree to evaluate enzymatic RNA manufacturing

Nitto Denko Avecia and EnPlusOne signed an evaluation agreement for the ezRNA enzymatic synthesis platform. The phased program covers proof-of-concept studies, laboratory process evaluation, and technology transfer at Avecia facilities. The platform uses a water-based, template-free process. The agreement evaluates manufacturing feasibility; it does not announce a completed commercial manufacturing contract or a definitive platform license.

Oligonucleotide Therapeutics & DeliveryAsk AI ↗
Integrated DNA Technologies

IDT and Aldevron launch research-grade base and prime editing RNA tools

IDT and Aldevron launched PE Ultra prime-editor mRNA, chemically modified pegRNAs, and six ABE8e-based editor mRNAs with a parallel screening kit. The companies also described guide-design support and stocked quantities from 20 micrograms to 1 milligram. These are research-use products; the announcement does not establish clinical safety, efficacy, or approval.

mRNA / LNP Oligonucleotide Therapeutics & DeliveryAsk AI ↗
Alnylam

Alnylam schedules five-year HELIOS-B follow-up at AHA

Alnylam announced AHA and ISA presentations covering vutrisiran in transthyretin amyloidosis, including five-year HELIOS-B follow-up with two years of open-label extension data. Planned analyses also examine exercise capacity, cardiopulmonary measures, and real-world treatment patterns. The announcement previews forthcoming presentations; open-label and post hoc analyses require interpretation distinct from randomized comparisons.

Oligonucleotide Therapeutics & DeliveryAsk AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗